Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Central Centrifugal Cicatricial Alopecia: Advances in Diagnosis and Treatment
Description
The talk focuses on Central Centrifugal Cicatricial Alopecia (CCCA), a common form of hair loss predominantly affecting Black women. The speaker, an assistant professor in Atlanta, emphasizes the importance of early diagnosis, explaining that CCCA often starts with patchy hair loss at the scalp's center and can progress to significant scarring and hair loss if not treated promptly. The presentation covers clinical findings through trichoscopy, advancements in genetic understanding, and the role of environmental factors, such as chemical relaxers historically associated with CCCA. The speaker shares insights from recent research, highlighting a genetic predisposition linked to mutations related to hair shaft formation. Treatment approaches involve topical corticosteroids deemed ultra-potent, intralesional corticosteroids, and systemic options like oral minoxidil and doxycycline, along with emerging therapies like topical metformin. The speaker underscores that despite the challenges of CCCA, effective treatment strategies can improve patient outcomes and quality of life. It stresses the necessity of proper hair care practices and regular scalp maintenance in conjunction with medical treatments to manage symptoms and halt progression.
View moreConclusions
- CCCA predominantly affects Black women and can begin as early as age 11, indicating a potential genetic predisposition.
- The prevalence of CCCA is estimated to be between 2% to 5.6%, with some reports in men suggesting lower incidence.
- CCCA is considered a scarring form of hair loss with limited potential for hair regrowth, necessitating a focus on halting disease progression.
- Genetic factors, especially mutations in the PADI3 gene, may play a significant role in the development of CCCA.
- There is a positive correlation between CCCA and other fibroproliferative disorders such as uterine fibroids and diabetes.
- Diagnosis of CCCA can be supported by clinical findings, trichoscopy, and, when necessary, biopsies, though not all cases require histological confirmation.
- Treatment recommendations include the use of ultra-potent topical corticosteroids, intralesional corticosteroids, and topical or oral minoxidil for managing CCCA.
- Aggressive treatment should be considered for patients with rapid disease progression, significant symptoms, or distinct clinical signs of inflammation.
- A Delphi consensus has prompted the development of treatment algorithms that include a combination of topical, intralesional, and systemic therapies tailored to the patients' needs.
- Counseling on hair care practices is crucial for managing symptoms and preventing exacerbation of CCCA.
- Callendar et al, 2012
- Jamerson et al, 2022
- Olsen et al, 2008, Dermatologic Therapy
- Dlova et al, 2014, JAAD, South Africa
- Jackson et al, JAAD, 2023
- Malki et al, 2019, NEJM
- Aguh et al, 2018, JAAD
- Dina et al, 2018, JAMA Dermatology
- Coogan et al, 2019, IJWD
- Roche et al, 2022, JAAD
- Araoye et al, 2020, JAAD Case Reports
- Yunes Panahi, Mohsen Taghizadeh, Eisa Tahmasbpour Marzony, Amirhossein Sahebkar, PMID: 25842469
- Gathers, 2009
- Olsen, 2011, JAAD